Covid

• The FDA has approved the oral antiviral ensitrelvir (Xocova), developed by Shionogi & Co, Ltd, for post-exposure prophylaxis (PEP) of COVID-19. • The treatment is authorized for use in adults and adolescents aged 12 years and older to prevent symptomatic SARS-CoV-2 infection. • Approval was based on the SCORPIO-PEP phase 3 trial, which demonstrated the drug's safety and efficacy in household contacts of symptomatic patients.

Registrations are up 7% in May, with battery electric vehicles recording the fastest growth and Tesla jumping 45%British car sales rose in May to their strongest level for the month since before the Covid pandemic, driven in part by strong growth from the Chinese manufacturers BYD and Chery.Car registrations rose 7% to 160,662 during the month, according to figures from the Society of Motor Manufacturers and Traders (SMMT), a lobby group. Continue reading...

• The U.S. FDA has approved ensitrelvir (Xocova), an oral antiviral developed by Shionogi, for the post-exposure prevention of COVID-19. • The medication is authorized for use in individuals aged 12 years and older who have been exposed to the SARS-CoV-2 virus. • This approval is significant as Xocova becomes the first and only oral medication specifically authorized to reduce the risk of infection after a known exposure.

• The FDA has approved Shionogi’s Xocova (ensitrelvir) as the first oral therapy designed to prevent Covid-19 after a person has been exposed to the virus. • The approval follows the Scorpio-Pep trial involving 2,387 participants aged 12 and older who were asymptomatic but had been exposed to a symptomatic household member. • The drug works by inhibiting viral replication, offering a critical new preventative tool for those who initiate treatment within 72 hours of their contact's symptom onset.

• The FDA has approved the oral medication ensitrelvir for use as post-exposure prophylaxis (PEP) to prevent the onset of COVID-19 symptoms. • Approval follows phase 3 clinical trial data conducted between February 10 and July 10, 2022, across 92 sites in Japan, Vietnam, and South Korea, demonstrating efficacy against Omicron variants. • This development is significant as it provides a preventative option for individuals exposed to the virus in high-risk environments, including nursing homes, acute care facilities, and during travel.

• Shionogi has received FDA approval for its protease inhibitor, ensitrelvir, specifically for use in the prevention of COVID-19. • This regulatory win follows a previous failure by the company to demonstrate the drug's effectiveness as a primary treatment for U.S. patients. • The approval is significant as it expands the available preventative options against the virus, leveraging a drug already approved in Japan.

• The FDA has approved ensitrelvir, an oral antiviral medication specifically designed to prevent COVID-19 after a person has been exposed to the virus. • Approval follows the phase III SCORPIO-PEP trial, which demonstrated that the drug reduced the risk of developing COVID-19 by more than half for individuals who were household contacts of an infected person. • This marks a significant shift in prevention strategy, though the medication is currently not approved for treating active COVID-19 infections within the U.S.